A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about ...

The two companies will also share costs and profits from the drug, which will start a phase 3 programme next year. The buy-in is another endorsement of Arvinas' PROTAC drugs, bifunctional ...

This Novo Nordisk drug is a combination of semaglutide with ... It is expected to become the first PROTAC ...

These are molecules — first described in a paper co-authored by Yale University researcher Craig Crews, founder of the first PROTAC-focused drug developer — that exploit naturally-occurring ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

The money will go toward work at the Center for Innovative Drug Discovery (CIDD), a joint venture between ... An innovative method they will develop is the Proteolysis-Targeting Chimeras (PROTAC) ...

However, drug resistance often occurs when tumors shift to alternative ... However, due to its strong cardiotoxicity, bufalin has limited translational potential. A PROTAC is a heterobifunctional ...